Obayashi, Yoshiaki
Mitsui, Satoshi
Sakamoto, Shinji
Minao, Nozomu
Yoshimura, Bunta
Kono, Toshiki
Yada, Yuji
Okahisa, Yuko
Takao, Soshi
Kishi, Yoshiki
Takeda, Toshihiko
Takaki, Manabu http://orcid.org/0000-0002-7371-2821
Yamada, Norihito
Article History
Received: 1 February 2019
Accepted: 15 August 2019
First Online: 18 October 2019
Compliance with ethical standards
: This study was approved by the research ethics committee of Okayama University Hospital and Okayama Psychiatric Medical Center.
: This work was supported in part by an award from the Dopamine Partial Agonist Society (Tokyo, Japan) (Manabu Takaki).N.Y. has received unrestricted research funding from Daiichi Sankyo, Eisai, Pfizer, Otsuka, Astellas, and Merck Sharp & Dohme, which was deposited into research accounts at Okayama University. N.Y. has received honoraria for his participation as a speaker at educational events from UCB Japan, Tsumura, Pfizer, Dainippon-Sumitomo, Daiichi-Sankyo, Merck Sharp & Dohme, Pfizer, Eisai, Meiji-Seika, and Mochida.M.T. has received honoraria for his participation as a speaker at educational events sponsored by Otsuka and Dainippon Sumitomo.S.S. has received unrestricted research funding from Eli Lilly, which was deposited into research accounts at Okayama University Hospital. S.S. has received honoraria for his participation as a speaker at an educational event sponsored by Otsuka.B.Y. has received honoraria for his participation as a speaker at educational events sponsored by Janssen.Y.O., S.M., N.M., T.K., Y.Y, Y.O., S.T., Y.K., and T.T. report no additional financial or other relationship relevant to this article.